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the patients, as well as resource-consuming for the health care
system. The ECON-APROS study has demonstrated that, besides
the importance clinical-wise to treat hypertensive patients in their
early stages of the disease, it is also cost-effective for the Greek
health care setting
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a rare
progressive and severe disease with short life expectancy. Bosen-
tan has been shown to slow PAH progression and improve func-
tional status, quality of life, and survival. The objective of the
study is to assess cost effectiveness of bosentan for the treatment
of PAH from a health care payer’s perspective in South Korea.
METHODS: A Markov model was used to estimate the expected
life years, quality-adjusted life years (QALYs) and costs for a
hypothetical cohort of 100 PAH patients treated for one year
with bosentan compared to iloprost. The health states included
in the model were WHO functional class I to IV and death.
Transition probabilities were calculated based on observed tran-
sitions for bosentan and iloprost. Utility values were borrowed
from an existing study, of which the utilities were calculated from
estimated EuroQol health states. Costs were comprised of medi-
cation, hospitalization, and monitoring. Medication and moni-
toring costs were estimated from the National Health Insurance
reimbursement data, with the latter based on expert opinion
while hospitalization costs were estimated from a teaching hos-
pital’s claims data for 13 patients. RESULTS: The model pre-
dicted that the expected life years of 100 PAH patients would be
98.5 years with bosentan and 98.4 years with iloprost while the
expected QALYs would be 51.1 QALYs and 33.1 QALYs, respec-
tively. The estimated costs would be 3,395 million KRW with
bosentan and 8,618 million KRW with iloprost. Treatment with
bosentan compared to treatment with iloprost resulted in a
greater gain in QALYs, though little gain in life years, with a
signiﬁcant cost saving. These ﬁndings were not substantially
affected by adjustments of transition probabilities, utility values,
or price of bosentan. CONCLUSION: Bosentan is more cost-
effective or cost-saving than iloprost for the treatment of PAH in
South Korea.
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OBJECTIVES: Acute decompensated heart failure (AHF) is a
leading cause of hospital admission. The Randomized EValua-
tion of Intravenous LeVosimendan Efﬁcacy (REVIVE II) trial
compared patients randomly assigned to levosimendan (levo) or
placebo (SOC), each in addition to local standard AHF treat-
ments. We report the REVIVE II economic analysis. METHODS:
REVIVE II enrolled patients (N = 600) hospitalized for AHF
remaining dyspneic at rest despite treatment with intravenous
diuretics. Case report forms documented index hospital treat-
ment (drug administration, procedures, days by care unit) as well
as subsequent admissions during 90 day follow-up. These data
were used to impute cost based on an econometric cost function
derived from >100,000 AHF hospital billing records selected per
REVIVE II inclusion criteria. RESULTS: Index admission mean
length of stay (LOS) was shorter for the levo group compared
with standard of care (SOC) (6.8 vs. 8.7 days, p = 0.007)
although ICU/CCU days were similar (levo 2.9, SOC 3.2,
p = 0.81). Excluding cost for levo, predicted mean (median) cost
for the index admission was levo $13,590 (9,458), SOC $19,021
(10,692) with a difference of $5,431 (1,234) favoring levo
(p = 0.04). During follow-up through end of study day 90,
no signiﬁcant differences were observed in hospital admis-
sions (p = 0.67), inpatient days (p = 0.81) or emergency visits
(p = 0.41). Subset analysis excluding patients with low baseline
blood pressure also showed lower cost for the index admission
for the levo group. Assuming an average price for levo in coun-
tries where is currently approved, incremental cost-effectiveness
of levo relative to SOC in this subset is less than $1000 per year
of life gained—a value well below accepted thresholds. CON-
CLUSION: In REVIVE II, patients treated with levo had shorter
LOS and lower cost for the initial hospital admission relative to
patients treated with SOC. When administered in accordance
with the current label, levo is highly cost-effective relative to
SOC.
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OBJECTIVES: Several drugs demonstrated the ability to reduce
cardiovascular events incidence in secondary prevention. Among
them we have aspirin, statins, beta-blockers and ACE-inhibitors.
We performed a cost effectiveness analysis of several therapeutic
options to assess their relative pharmacoeconomic performance.
METHODS: We built a Markov model to simulate the survival
rate and the cardiovascular events frequency in a high cardiovas-
cular risk cohort formed by Italian patients who already had
an acute myocardial infarction. Secondary prevention strate-
gies considered were: C—standard therapy; R—ramipril plus
standard therapy; S—simvastatin plus standard therapy;
P—pravastatin plus standard therapy; R + S—ramipril and sim-
vastatin plus standard therapy; R + P—ramipril and pravastatin
plus standard therapy. Treatment efﬁcacy values were based on
the ﬁndings of the HOPE study for ramipril, the HPS study for
simvastatin, the LIPID, WOSCOPS and CARE for pravastatin.
Time horizon of the simulation was cohort lifetime. Direct sani-
tary costs were considered and valued according to current
national prices, tariffs, and published literature. RESULTS: The
average life expectance resulted from the simulation was 12.0
in C, 12.9 in R, 12.7 in S, 13.1 in P, 13.6 in R + S and 14.0 in
R + P strategies. The incremental cost effectiveness ratios
(ICERs) with respect to C strategy were 1241 Euro/Life Year
(LY) in R, 7610 Euro/LY in S, 7315 Euro/LY in P, 4660 Euro/LY
in R + S and 5192 Euro/LY in R + P strategies. CONCLUSION:
The simulation showed that the associations between ramipril
and statins are the most effective strategies. From the economic
standpoint ramipril alone is largely the most cost-effective strat-
egy. This is mainly due to the lower cost of the drug with
respect to statins.
A412 Abstracts
